HEPA News and Press, Hepion Pharmaceuticals Inc. From 12/29/20

Hepion Pharmaceuticals (HEPA) announces that an independent Data Safety Monitoring Board has approved the continuation of the company's Phase 2a clinical trial for its lead asset CRV431 in NASH (non-alcoholic steatohepatitis) patients with moderate-to-severe fibrosis.The two evaluat...

- DSMB Review After Completion of the First Dose Cohort Affirmed No Safety or Tolerability Concerns with CRV431 in NASH Patients - - DSMB Recommended the AMBITION Study Continue with Final Dosing Cohort - - Final Cohort Expected to be Completed in Early 2021 - EDISON, NJ / ACCE...

The FDA has signed off investigational new drug application for Hepion Pharmaceuticals' ([[HEPA]] -2.4%) CRV431, a cyclophilin inhibitor for the treatment of COVID-19, and the candidate is poised to move directly into Phase 2 study."Although Hepion's focus and lead indication remain...

- IND Expands Potential Indications for CRV431 Beyond NASH to Include COVID-19 - - CRV431 Poised to Move Directly into Phase 2 Clinical Study for COVID-19 - - Company May Seek Partnership(s) for COVID-19 Drug Development - EDISON, NJ / ACCESSWIRE / December 22, 2020 / Hepio...

Will These Biotech Penny Stocks Continue to See Adoration From Investors? Biotech penny stocks have become some of the most popular investments throughout the pandemic. Prior to this, biotech stocks were also quite popular, but not to the extent that they are now in my opinion. With...

Hepion Pharmaceuticals ([[HEPA]] +10.8%) has announced that, in addition to completing dosing in 75mg CRV431 cohort of its Phase 2a AMBITION trial, Hepion has dosed the first non-alcoholic steatohepatitis ((NASH)) patient in 225 mg cohort.The study is designed to assess safety, tole...

EDISON, NJ / ACCESSWIRE / December 10, 2020 / Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA)("Hepion"), a clinical stage biopharmaceutical company focused on Artificial Intelligence ("AI")-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis ("NASH") and liver d...

Hepion Pharmaceuticals (HEPA) has announced results from a translational research study in which its lead drug candidate, CRV431 decreased formation of a class of blood platelets, called ‘procoagulant platelets, and high levels of such platelets are associated with trans...

- CRV431 May Reduce Risk of NASH-Associated Ischemic Stroke - EDISON, NJ / ACCESSWIRE / December 2, 2020 / Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence ("AI")-driven therapeutic drug development for the treatme...

Includes Full Exercise of Underwriters' Overallotment Option EDISON, NJ / ACCESSWIRE / November 30, 2020 / Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence ("AI")-driven therapeutic drug development for the treatm...